[Safety and feasibility of 120 min rapid infusion regimen of daratumumab in patients with multiple myeloma]

Zhonghua Xue Ye Xue Za Zhi. 2023 Aug 14;44(8):696-699. doi: 10.3760/cma.j.issn.0253-2727.2023.08.017.

[Article in Chinese]

Authors

T H Wang¹, R Hao¹, B N Xu¹, L Chang¹, Z B Liu¹, J L Yao¹, W Wang¹, W J Xie¹, W W Yan¹, Z J Xiao¹, L G Qiu¹, G An¹

Affiliation

¹ State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.

PMID: 37803849
PMCID: PMC10520231
DOI: 10.3760/cma.j.issn.0253-2727.2023.08.017

No abstract available

MeSH terms

Antibodies, Monoclonal / adverse effects
Antineoplastic Combined Chemotherapy Protocols
Dexamethasone / therapeutic use
Feasibility Studies
Humans
Multiple Myeloma* / drug therapy

Substances

daratumumab
Antibodies, Monoclonal
Dexamethasone